7 maart 2022, 09:43
|
#6
|
Secretaris-Generaal VN
Geregistreerd: 13 mei 2015
Locatie: Vlaams-Brabant
Berichten: 76.160
|
Citaat:
Oorspronkelijk geplaatst door Hoofdstraat
Dat is juist het punt, dit is geen preprint. Het zijn 2 grote studies, in 2 verschillende landen, 2 verschillende methodes, met een grote groep patienten en peer reviewed.
|
Neen het is een Youtubefilmpje over dubieuze ‘studies’.
Ik heb eens de moeite gedaan om die ‘peer reviewed publicatie’ op te zoeken:
https://healthfeedback.org/claimrevi...e-conclusions/
Interestingly, the authors acknowledged this issue in the Discussion: “Due to the large number of participants, this citywide program was unable to supervise whether ivermectin users were using ivermectin regularly, in the correct dose and interval proposed.” But they didn’t fully account for its potential effects on their findings, instead simply suggesting that their findings underestimated ivermectin’s beneficial effects, implying that the true benefit was even larger. While that is one possibility, the authors didn’t appear to consider how the problems above may have also obscured a potential absence of benefit or even harm from ivermectin treatment. There isn’t evidence to support the a priori assumption that ivermectin treatment can only lead to improvement.
In his concluding remarks, Meyerowitz-Katz called it “a very weak observational study” that gave us “no useful information at this point in the ivermectin literature”:
Finally, at least two of the authors, Flavio Cadegiani and Juan Chamie, are members of a group called the Front Line COVID-19 Critical Care Alliance (FLCCC). This group, led by physicians Pierre Kory and Paul Marik, propagated unsupported claims about ivermectin as an effective COVID-19 treatment. Cadegiani is also the principal investigator of a clinical trial that is being investigated for potential violations of medical ethics and human rights by Brazil’s National Health Council, as reported by the British Medical Journal. Cadegiani and Lucy Kerr also have financial conflicts of interest from their work for a company that produces ivermectin.
|
|
|